DxS Announces Plans to Expand its Manufacturing Capacity
Company also announces Award of ISO 13485 certification
DxS has announced plans to expand its manufacturing facilities, and to significantly increase the number of staff. In addition, the Company has also been awarded the ISO 13485:2003 quality certification for the "design, development and manufacture of molecular diagnostic products for human genetic analysis".
DxS will take on more specialised manufacturing space at its current site in Manchester, and intends to have doubled in size over the coming months. The expansion of DxS' manufacturing capabilities will also see an increase in staff, with further appointments expected during 2008 as these new facilities and other departments are expanded.
The increase in demand follows the recent announcement that Amgen selected the DxS TheraScreen® K-RAS assay as the preferred method of assessing a patient's K-RAS mutation status, in order to support sales of Vectibix®, Amgen's colorectal cancer therapy.
Dr Stephen Little, CEO of DxS said: "The achievement of ISO 13485 certification underlines our commitment to provide the highest standards in our products and services, and demonstrates our ability to consistently meet customer and regulatory requirements."
Other news from the department manufacturing
